Document Detail

Renin inhibitors in hypertension.
MedLine Citation:
PMID:  1959244     Owner:  NLM     Status:  MEDLINE    
The renin-angiotensin system (RAS) is an important modulator of blood pressure and fluid balance. The clinical success of angiotensin converting enzyme inhibitors (ACEIs) in the treatment of hypertension has stimulated the search for antagonists of renin. Because renin is highly specific for its substrate, angiotensinogen, renin inhibitors may emerge as clinically preferable alternatives to ACEIs, which affect multiple biological systems, including bradykinin and prostaglandin metabolism. Recent advances in renin inhibitor chemistry have produced highly specific and potent, transition-state analogs of angiotensinogen. Several compounds (e.g., enalkiren, ditekiren, CGP 38560A, and RO 42-5892) have been tested in man. These renin inhibitors produce dose-dependent decreases in plasma renin activity (PRA) which are dissociated from the dose-dependent decreases in blood pressure (BP). Potential explanations for this dissociation include methodologic errors in PRA assays and alternate sites or mechanisms of drug action, including inhibition of noncirculating tissue renin. A prolonged hypotensive effect is seen following single doses of enalkiren and RO 42-5892, and repeated dosing with enalkiren results in sustained hypotensive effect without tachyphylaxis. Renin inhibitors can reduce blood pressure irrespective of baseline renin status and sodium balance. However, high-renin patients generally respond more vigorously, and the hypotensive response is enhanced by sodium depletion. In general, renin inhibitors have been safe and well tolerated in limited clinical studies. New generation renin inhibitors with higher potency and greater oral bioavailability may join the antihypertensive armamentarium.
R R Luther; H N Glassman; R S Boger
Related Documents :
2193544 - Hemodynamic and hormonal effects of renin inhibition in ovine heart failure.
11882574 - Phospholipase d contributes to transmural pressure control of prorenin processing in ju...
7473514 - Evidence for cardiovascular effects of prorenin.
1756444 - Active and inactive renin in human forearm of hypertensive patients.
10411844 - Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock.
1414544 - Sedatives and antagonists in the management of severely head-injured patients.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical nephrology     Volume:  36     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1992-01-09     Completed Date:  1992-01-09     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  181-6     Citation Subset:  IM    
Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Dipeptides / therapeutic use
Hypertension / drug therapy*
Oligopeptides / therapeutic use
Renin / antagonists & inhibitors*,  therapeutic use
Renin-Angiotensin System / drug effects*
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Dipeptides; 0/Imidazoles; 0/Oligopeptides; 103336-05-6/ditekiren; 113082-98-7/enalkiren; 122088-76-0/CGP 38560; 135669-48-6/remikiren; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnostic procedure in renovascular hypertension.
Next Document:  Predictive value of thallium-201-dipyridamole myocardial stress scintigraphy in chronic hemodialysis...